153 related articles for article (PubMed ID: 35688842)
21. Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.
Byeon S; Cho HJ; Jang KT; Kwon M; Lee J; Lee J; Kim ST
ESMO Open; 2021 Feb; 6(1):100002. PubMed ID: 33399091
[TBL] [Abstract][Full Text] [Related]
22. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
23. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
25. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
[TBL] [Abstract][Full Text] [Related]
26. Lack of distinct molecular profile of Primary Dermal Melanoma.
Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
[TBL] [Abstract][Full Text] [Related]
27. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
28. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes.
Wang M; Banik I; Shain AH; Yeh I; Bastian BC
Genome Med; 2022 Jun; 14(1):65. PubMed ID: 35706047
[TBL] [Abstract][Full Text] [Related]
29. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ; Sinnberg T; Gschwind A; Niessner H; Demidov G; Amaral T; Ossowski S; Bonzheim I; Röcken M; Riess O; Garbe C; Schroeder C; Forschner A
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825510
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
Ticha I; Hojny J; Michalkova R; Kodet O; Krkavcova E; Hajkova N; Nemejcova K; Bartu M; Jaksa R; Dura M; Kanwal M; Martinikova AS; Macurek L; Zemankova P; Kleibl Z; Dundr P
Sci Rep; 2019 Nov; 9(1):17050. PubMed ID: 31745173
[TBL] [Abstract][Full Text] [Related]
31. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
[TBL] [Abstract][Full Text] [Related]
32. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
33. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.
Griewank KG; Schilling B
Am J Clin Dermatol; 2017 Jun; 18(3):303-310. PubMed ID: 28229402
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
Rajkumar S; Watson IR
Br J Cancer; 2016 Jul; 115(2):145-55. PubMed ID: 27336610
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
[TBL] [Abstract][Full Text] [Related]
39. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract][Full Text] [Related]
40. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
